Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Kristen M ZarrellaDepartment of Immunology & Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0003-3142-6664
Ryan M SheridanRNA Bioscience Initiative, University of Colorado School of Medicine, Aurora, CO, USA.
Brian C WareDepartment of Immunology & Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Bennett J DavenportDepartment of Immunology & Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0001-8155-191X
Mariana O L da SilvaDepartment of Immunology & Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Dariia VyshenskaVirology Division, Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA.
Aspen U MartinDepartment of Biochemistry & Molecular Genetics, University of Colorado School of Medicine, Aurora, CO, USA.
Nick A MayDepartment of Immunology & Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0002-8662-2091
Daniela WeiskopfCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0003-2968-7371
Jay R HesselberthRNA Bioscience Initiative, University of Colorado School of Medicine, Aurora, CO, USA.
Daniel N StreblowVaccine and Gene Therapy Institute and Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.
Alex L GreningerVirology Division, Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA.ORCID 0000-0002-7443-0527
Thomas E MorrisonDepartment of Immunology & Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0002-1811-2938
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Screening CoreU19AI109680 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WHITLEY, RICHARD J. · 2014 to 2018
$34.9M
TRAINING PROGRAM IN IMMUNOLOGYT32AI007405 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Laurel L Lenz, Raul Martin Torres · 1991 to 2026
$10.5M
Large Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination75N93019C00065 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI MITCHELL, MAYA · 2019 to 2023
$7.3M
Predoctoral Training Program in Molecular and Cellular Biology (Supplement: Mentoring in the Research Environment)T32GM136444 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI MICHAEL A MCMURRAY, Rytis Prekeris · 2020 to 2026
$3.7M
Biochemistry at single-cell resolution: a new approach to understand functional heterogeneityR01AG071467 · NIA · UNIVERSITY OF COLORADO DENVER · PI HESSELBERTH, JAY R · 2020 to 2024
$3.2M
Impairment of B cell Responses by Pathogenic Chikungunya VirusesR01AI141436 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DIAMOND, MICHAEL S, MORRISON, THOMAS E · 2019 to 2023
$3.2M
Alphavirus Pathogenesis and ImmunityR01AI185051 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Michael S Diamond, Thomas E Morrison · 2025 to 2026
$1.6M
Defining mechanisms of chronic CHIKV disease in joint associated tissueF32AI188869 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ZARRELLA, KRISTEN · 2025 to 2025
Arthritogenic alphaviruses including chikungunya, Mayaro, and Ross River viruses cause long-lasting musculoskeletal pain and inflammation. However, mechanisms driving chronic disease remain poorly understood. Here, we investigated joint-associated tissues in alphavirus-infected mice at a late stage of infection. Utilizing scRNA-seq, spatial transcriptomics, and flow cytometry we identified an accumulation of inflammatory macrophages in joint-associated tissues with elevated
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Chikungunya virus persists in joint-associated macrophages and promotes chronic disease. · full record | OpenQuestion